hVIVO #HVO – Influenza HCT contract signed with Traws Pharma & launch of unified brand identity April 14, 2026 – Posted in: Blog, hVIVO (HVO)

London, UK – 14 April 2026 hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will test Traws’ prophylactic antiviral candidate, tivoxavir marboxil (“TXM”), using the hVIVO Influenza Human Challenge…

Open Orphan #ORPH – Trading Update, Volunteer Recruitment and Laboratory Facilities Expansion March 8, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the year ended 31 December 2021. The Company also announces it will be opening a new primary FluCamp volunteer recruitment screening facility in Plumbers Row, London (“Plumbers Row Facility”) and a secondary FluCamp recruitment facility in Manchester. Trading Update Subject to completion…

hVIVO #HVO – Influenza HCT contract signed with Traws Pharma & launch of unified brand identity April 14, 2026 – Posted in: Blog, hVIVO (HVO)

Open Orphan #ORPH – Trading Update, Volunteer Recruitment and Laboratory Facilities Expansion March 8, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL